Neogen Target of Unusually Large Options Trading (NASDAQ:NEOG)

08 Jan 2026, 11:38 by Doug Wharley · The Cerbat Gem

Neogen Corporation (NASDAQ:NEOG – Get Free Report) was the recipient of some unusual options trading activity on Thursday. Investors bought 4,518 call options on the company. This is an increase of 426% compared to the average volume of 859 call options.

Neogen Stock Performance

NASDAQ:NEOG traded up $2.42 during midday trading on Thursday, reaching $9.80. The stock had a trading volume of 7,275,367 shares, compared to its average volume of 3,893,411. The stock has a market capitalization of $2.13 billion, a P/E ratio of -2.03 and a beta of 1.96. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.58 and a quick ratio of 2.26. Neogen has a 1-year low of $3.87 and a 1-year high of $12.98. The firm’s fifty day simple moving average is $6.52 and its 200-day simple moving average is $5.83.

Neogen (NASDAQ:NEOG – Get Free Report) last announced its earnings results on Thursday, January 8th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.03. Neogen had a positive return on equity of 2.23% and a negative net margin of 117.61%.The firm had revenue of $224.69 million during the quarter, compared to the consensus estimate of $208.50 million. During the same quarter in the prior year, the company earned $0.11 EPS. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. On average, equities research analysts forecast that Neogen will post 0.38 EPS for the current fiscal year.

Key Neogen News

Here are the key news stories impacting Neogen this week:

Positive Sentiment: Revenue beat vs. street estimates — Neogen reported total Q2 revenue of roughly $224.7M, above consensus (roughly $208–212M), showing better-than-expected sales that helped lift the stock. Neogen Corporation (NEOG) Releases Q2 2026 Earnings
Positive Sentiment: Full‑year revenue guidance raised and above consensus — Management set FY2026 revenue guidance of $845M–$855M, higher than the street’s prior ~$824.5M consensus, giving investors a clearer path for recovery. Neogen FY2026 Slide Deck / Press Release
Positive Sentiment: Management disclosure and presentation available — Company slide deck and earnings materials were posted (helps transparency for investors). Neogen Q2 Results — Earnings Call Presentation
Neutral Sentiment: Analyst coverage remains mixed/centred on “hold” sentiment with median price targets below recent trading — analysts and consensus sentiment are cautious despite the beat/guidance. Quiver Quantitative NEOG Coverage
Neutral Sentiment: Small insider purchase noted — CEO purchased a modest number of shares, a signal some investors view as alignment but size is immaterial. Insider Activity Detail
Negative Sentiment: Operating and net losses, cash flow weakening — the company recorded an operating loss (~-$5.4M) and a net loss (~-$15.9M) with cash from operations down sharply year‑over‑year, which raises near‑term profitability concerns. Detailed Financials and Loss Metrics
Negative Sentiment: Mixed/conflicting EPS reporting — some outlets note an EPS beat (MarketBeat reported $0.10) while others report a diluted EPS loss (~-$0.07); the inconsistency can fuel volatility and investor uncertainty. MarketBeat Q2 Release Quiver Quantitative EPS Reporting
Negative Sentiment: Revenue still down YoY and capex rising — Q2 revenue declined ~2.8–2.9% vs. prior year and capital expenditures increased (~40%), which pressures margins and cash flow until sales stabilize. Q2 Trends and Capex Detail

Hedge Funds Weigh In On Neogen

Several large investors have recently added to or reduced their stakes in NEOG. Savant Capital LLC acquired a new stake in Neogen during the second quarter worth $50,000. Tudor Investment Corp ET AL acquired a new stake in shares of Neogen during the 3rd quarter valued at about $62,000. Coldstream Capital Management Inc. bought a new stake in Neogen in the third quarter valued at about $64,000. Cresset Asset Management LLC bought a new stake in Neogen in the second quarter valued at about $53,000. Finally, Evergreen Capital Management LLC bought a new position in Neogen during the second quarter worth about $56,000. Institutional investors and hedge funds own 96.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on NEOG. Wall Street Zen upgraded shares of Neogen from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Piper Sandler set a $6.50 price target on Neogen and gave the company a “neutral” rating in a research note on Thursday, October 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neogen in a research report on Monday, December 29th. Finally, CJS Securities upgraded shares of Neogen from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research note on Wednesday, December 10th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Neogen presently has an average rating of “Hold” and a consensus price target of $8.83.

Get Our Latest Research Report on Neogen

About Neogen

(Get Free Report)

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.